Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma

Published On 2023-12-04 09:30 GMT   |   Update On 2023-12-04 12:19 GMT
Advertisement

Bangalore: Syngene International has announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma Ltd as announced on 4 July 2023. The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted from the earlier gross value of Rs 702 crores. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma Ltd.

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing. The Unit has been acquired effective 1st December 2023 on payment of Rs 395 crores. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma Ltd.

Read also: Evaluate safety in proposed study: CDSCO Panel tells Syngene on Suplatast Tosilate Capsule

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.

Read also: Syngene International reports 14.22 percent increase in net profit at Rs 116.5 crore in Q2

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News